X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (296) 296
Publication (48) 48
Newsletter (41) 41
Book Review (4) 4
Newspaper Article (4) 4
Book Chapter (3) 3
Conference Proceeding (2) 2
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
romidepsin (334) 334
index medicus (176) 176
humans (155) 155
oncology (107) 107
cancer (104) 104
histone deacetylase inhibitor (84) 84
vorinostat (70) 70
histone deacetylase inhibitors (67) 67
t-cell lymphoma (55) 55
care and treatment (53) 53
hematology (52) 52
pharmacology & pharmacy (52) 52
depsipeptides - pharmacology (51) 51
female (51) 51
male (50) 50
t cells (50) 50
apoptosis (48) 48
research (48) 48
histone deacetylase inhibitors - pharmacology (46) 46
depsipeptides - therapeutic use (45) 45
histone deacetylase inhibitors - therapeutic use (43) 43
expression (42) 42
non-hodgkin's lymphomas (42) 42
animals (40) 40
chemotherapy (40) 40
depsipeptide (40) 40
hdac inhibitors (40) 40
middle aged (40) 40
phase-ii trial (40) 40
aged (37) 37
adult (36) 36
suberoylanilide hydroxamic acid (36) 36
drug therapy (35) 35
treatment outcome (35) 35
cell line, tumor (33) 33
histone deacetylase (32) 32
lymphomas (32) 32
depsipeptide fr901228 (31) 31
trial (31) 31
epigenetics (29) 29
antibiotics, antineoplastic - therapeutic use (28) 28
article (28) 28
belinostat (28) 28
cutaneous t-cell lymphoma (28) 28
analysis (27) 27
panobinostat (27) 27
therapy (27) 27
fk228 (26) 26
gene expression (26) 26
lymphoma (26) 26
acetylation (25) 25
depsipeptides - adverse effects (25) 25
health aspects (25) 25
antineoplastic agents - therapeutic use (24) 24
histone deacetylases - metabolism (23) 23
lymphoma, t-cell, peripheral - drug therapy (23) 23
open-label (23) 23
antineoplastic combined chemotherapy protocols - therapeutic use (22) 22
pralatrexate (22) 22
tumors (22) 22
cell biology (21) 21
histone deacetylase inhibitors - adverse effects (21) 21
lymphoma, t-cell, cutaneous - drug therapy (21) 21
multicenter (21) 21
phase-ii (21) 21
antineoplastic agents - pharmacology (20) 20
bortezomib (20) 20
mycosis-fungoides (20) 20
apoptosis - drug effects (19) 19
brentuximab vedotin (19) 19
cell proliferation - drug effects (19) 19
depsipeptides - administration & dosage (19) 19
dosage and administration (19) 19
intellectual property (19) 19
neoplasms - drug therapy (19) 19
peripheral t-cell lymphoma (19) 19
epigenetic inheritance (18) 18
aged, 80 and over (17) 17
medicine & public health (17) 17
reports (17) 17
transplantation (17) 17
clinical trials (16) 16
mice (16) 16
prognosis (16) 16
sezary-syndrome (16) 16
activation (15) 15
antibiotics, antineoplastic - pharmacology (15) 15
chromobacterium-violaceum no-968 (15) 15
combination (15) 15
drug approval (15) 15
gemcitabine (15) 15
proteins (15) 15
antibiotics, antineoplastic - adverse effects (14) 14
antineoplastic agents (14) 14
hemic and lymphatic diseases (14) 14
resistance (14) 14
chemistry, medicinal (13) 13
clinical trials as topic (13) 13
fr901228 (13) 13
genetic aspects (13) 13
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Oncotarget, ISSN 1949-2553, 2016, Volume 7, Issue 4, pp. 4454 - 4467
Journal Article
Leukemia & Lymphoma, ISSN 1042-8194, 03/2019, Volume 60, Issue 4, pp. 912 - 919
We investigated GDP (gemcitabine, 1000 mg/m 2 IV d1, d8; dexamethasone, 40 mg po d1-4; cisplatin, 75 mg/m 2 IV d1) combined with romidepsin on days 1 and 8... 
Non-Hodgkin lymphoma | phase I trial | combination therapy | romidepsin
Journal Article
Journal of Investigative Dermatology, ISSN 0022-202X, 09/2019, Volume 139, Issue 9, pp. 1975 - 1984.e2
FK228 (romidepsin) and suberoylanilide hydroxamic acid (vorinostat) are histone deacetylase inhibitors (HDACi) approved by the US Food and Drug Administration... 
PROTEIN | ROMIDEPSIN | LANDSCAPE | CONSTITUTIVE ACTIVATION | TRANSCRIPTION | PROTEASOME | LYMPHOMA | DNA-REPAIR | SOMATIC MUTATIONS | VORINOSTAT | DERMATOLOGY
Journal Article
ACTA MEDICA OKAYAMA, ISSN 0386-300X, 10/2019, Volume 73, Issue 5, pp. 469 - 474
Romidepsin is an important therapeutic option for patients with peripheral T-cell lymphoma (PTCL). However, the timing of romidepsin administration remains... 
SALVAGE CHEMOTHERAPY | MEDICINE, RESEARCH & EXPERIMENTAL | GDP | peripheral T-cell lymphoma not otherwise specified | romidepsin | angioimmunoblastic T-cell lymphoma | gemcitabine | cisplatin
Journal Article
Hematological Oncology, ISSN 0278-0232, 06/2019, Volume 37, Issue S2, pp. 335 - 335
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2015, Volume 33, Issue 23, pp. 2492 - 2499
Journal Article
Oncotarget, 05/2019, Volume 10, Issue 33, p. 3104
Studies have examined gene expression changes in Sézary syndrome (SS), but disease pathogenesis remains largely unknown, and diagnosis and treatment are... 
Journal Article
Oncotarget, ISSN 1949-2553, 03/2019, Volume 10, Issue 20, p. 1860
Journal Article
Blood, ISSN 0006-4971, 06/2018, Volume 131, Issue 26, pp. 2899 - 2905
T-cell chronic active Epstein-Barr virus (CAEBV) is a rare disease in which EBV is present predominantly in T cells that infiltrate the tissues; patients have... 
ROMIDEPSIN | INHIBITION | PROGNOSTIC-FACTORS | EBV INFECTION | NONIMMUNOCOMPROMISED HOSTS | INFECTED CELLS | COMPLETE RESPONSES | GANCICLOVIR | HEMATOLOGY | LYMPHOCYTES | CHILDREN | How I Treat
Journal Article
Clinical Lymphoma Myeloma and Leukemia, ISSN 2152-2650, 09/2017, Volume 17, pp. S168 - S169
Journal Article
Cancer Biology & Therapy, ISSN 1538-4047, 10/2016, Volume 17, Issue 10, pp. 1094 - 1106
We investigated the cytotoxic interactions of romidepsin, a histone deacetylase inhibitor, and lenalidomide, an immunomodulatory agent, in a T-cell lymphoma... 
Lenalidomide | romidepsin | tumor cell death | T-cell lymphoma | synergistic interaction | HDAC INHIBITORS | APOPTOSIS | CLINICAL-TRIAL | FK228 DEPSIPEPTIDE | OPEN-LABEL | THIOREDOXIN SYSTEM | COMBINATION | THERAPY | ONCOLOGY | STRESS | UP-REGULATION
Journal Article
by Liang, T and Hou, XB and Zhou, Y and Yang, XY and Fang, H
ACS MEDICINAL CHEMISTRY LETTERS, ISSN 1948-5875, 08/2019, Volume 10, Issue 8, pp. 1122 - 1127
Histone deacetylase 6 (HDAC6) has emerged as a promising drug target for various human diseases, including diverse neurodegenerative diseases and cancer.... 
HISTONE DEACETYLASE INHIBITOR | CHEMISTRY, MEDICINAL | ROMIDEPSIN | 2,4-imidazolinedione | isoform-selective | apoptosis | antiproliferative | PANOBINOSTAT | HDAC6
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.